



Positively Charged Surface Chemistry for Biological Separations

Peter Pellegrinelli Conner McHale, Stephanie Schuster, Ben Libert

Advanced Materials Technology, Inc.

Overview

HALO


- The advantages of a positively charged surface column with Fused-Core[®] technology
- Improvement of peak shape for basic compounds using MS-friendly mobile phases for both small molecule and peptide analysis. Why is using low ionic strength mobile phase desirable?
- How a positively charged surface column chemistry benefits LC & LCMS separations including loading capacity improvement gains.
- Applications of the PCS Peptide phase and comparisons




Fused-Core[®] Technology


HALO

HALO 90 Å, 2.7 μm





Superficially Porous Particle (SPP)




Fully Porous Particle (FPP)



Power of Fused-Core[®] Technology

HALO





Positively Charged Surface Stationary Phase

When do we need a Positively Charged Stationary Phase?

HALO

- When running low ionic strength mobile phase with formic acid for LC and LC-MS applications for
 - Basic compounds
 - Peptides
 - Protein digests






Why do we need a Positively Charged Stationary Phase?

HALO

- When basic compounds are run at low pH, they gain a proton and become positively charged.
- At low sample loads, the tailing will be symmetrical using formic acid containing mobile phases.
- At high sample loads, the tailing will become significant and the peak shape will suffer.






Peptide Separations in Acidic MP

HALO

Improving Retention and Peak Shape Using Ammonium Formate




McCalley, D. V., Effect of buffer on peak shape of peptides in reversed-phase high performance liquid chromatography. *J Chromatogr* **2004**, *1038* (1-2), 77-84. Schuster, S. A.; Boyes, B. E.; Wagner, B. M.; Kirkland, J. J., Fast high performance liquid chromatography separations for proteomic applications using Eused-Core[®] silica particles. *J Chromatogr* **2012**, 1228, 232-241.



Load Effects for Peptides Comparing Acids

HALO




Reference: Johnson, D.J., Boyes, B.E., Orlando, R.C. The Use of Ammonium Formate as a Mobile-Phase Modifier for LC-MS/MS Analysis of Tryptic Digests. **2013** *J. Biomol.Tech.*, 24, 187-197.



icedmaterialstechnology

Example of HALO[®] PCS C18 Peptide

HALO




🤰 advancedmaterialstechnology

Loading Capacity Improvement Gains

Peptide Load Tolerance

HALO

1, 5, 10, and 15µL injections of synthetic peptides (0.3µg/µL peptides) on 4.6x100mm




Insulin Chain B; 3496 Da



Peptide Load Tolerance (2)

HALO

1, 5, 10, and 15µL injections of synthetic peptides (0.3µg/µL peptides) on 4.6x100mm




Ac-RGVVGLYLGK-NH2 (1102 Da)



Applications of the PCS C18 Peptide Phase

HALO[®] PCS C18 Peptide: Rapid Separation




Low Abundance Peptide Analysis

1. Uracil 15μL injection of Synthetic Peptide Standard (0.3μg/μL) Sequence: RGAGGLYLGK-NH2 2. S1Y 1.5mL/min, 0-35%B in 10min, 30°C; 280nm A=0.1%Formic; B=0.1%Formic in ACN Sequence: Ac- RGGGGLYLGK- NH2 3. S2Y S3Y Sequence: Ac- RGAGGLYLGK- NH2 4. 5. S4Y2 Sequence: Ac- RGVGYLGLGK- NH2 Peak Capacity: 201 S5Y Sequence: Ac- RGVVGLYLGK- NH2 6. Insulin Chain B oxidized 7. From load tolerance advantage.. 160Å PCS C18 Increased resolution on PCS Peak Capacity: 98 160Å C18 3 6 0.0 1.0 2.0 3.0 4.Ò 5.0 6.Ò 7.0 8.0 9.Ò 10.0

www.advancedmaterialstechnology

Trastuzumab Tryptic Digest: Higher Peak Capacity with 160 Å PCS C18

advancedmaterialstechnology



0.4mL/min; 60°C; 3-50% in 30 min; A=0.1% Formic Acid in H₂O B=0.1% Formic Acid in ACN Shimadzu NexeraX2 -> divert valve -> QExactive HF (res=240,000)


MarvelXACT post-column plumbing: Peptide C18 and PCS C18

- 50µmx350mm from column to divert
- 50μmx350mm from divert valve to union
- 50µmx150mm from grounding union to HESI II

HALO 160Å PCS vs Competitor

vancedmaterialstechnology

HALO





Using PCS with Trifluoracetic Acid

160Å PCS C18 2.1x100mm 2.7μm SPP versus Competitor 130Å 2.5μm FPP S1Y S2Y S5Y S3Y 1µl injection of peptide S4Y2 Uracil 90000 130Å standard (0.3mg/mL), charged Gradient 2-35%B in 10min Insulin B 80000 C18 at 0.3mL/min 30°C, 280nm FPP 0.1% Formic 70000 on NexeraX2 60000 PCS A=H2O + acid modifier(s) 0.1% Formic C18 B=ACN + acid modifier(s) 50000 Initial FA-only 40000 30000 PCS * 0.1% Formic 20000] C18 0.02% TFA * unknown 10000 Peptide retention times Same-day Revert to "initial" after PCS PCS Exposed to 0.02% TFA + 0.1%FA 0.1% Formic C18 Final FA-only -10000 S1Y S2Y S3Y S5Y Insulin **B** Uracil S4Y2 -20000 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0

advancedmaterialstechnology

Summary

HALO

- HALO® PCS C18 exhibits favorable peak shape for various small molecule bases/peptides in weakly acidic mobile phase (0.1% Formic).
- Improved peak shape vs traditional C18
- Improved load tolerance vs traditional C18
- Improved ionization efficiencies when using formic acid
- PCS C18 can be used with other acids such as TFA or DFA







halocolumns.com



3521 Silverside Road, Suite 1-K Quillen Building Wilmington, DE 19810

in



(302) 992-8060

YOU

Tube

ISO 9001 QMS certified All operations in Wilmington, DE Global distribution

